Effectiveness, survival and safety of guselkumab attending to basal characteristics in moderate-to-severe psoriatic patients: a cohort study

Background: Psoriasis is a chronic inflammatory disease which can impact quality of life. In the past decade multiple biologic treatments have been released with encouraging results. Guselkumab is a monoclonal antibody targeting IL-23p19. Multiple randomized clinical trials have demonstrated its eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Villaverde, Ricardo, Rodriguez-Fernandez-Freire, Lourdes, Armario-Hita, Jose C., Pérez-Gil, Amalia, Vasquez Chinchay, Fiorella, Galán-Gutiérrez, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2022
Materias:
Clinical Practice Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755754/
https://www.ncbi.nlm.nih.gov/pubmed/36567685
http://dx.doi.org/10.12688/f1000research.122945.2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755754/
https://www.ncbi.nlm.nih.gov/pubmed/36567685
http://dx.doi.org/10.12688/f1000research.122945.2

Ejemplares similares